Regeneron’s Combination Therapy Fails Late-Stage Trial Against Keytruda
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 59 minutes ago
0mins
Should l Buy REGN?
Source: seekingalpha
- Trial Failure: Regeneron (REGN) announced that its late-stage trial failed to meet the primary endpoint of progression-free survival against Merck’s (MRK) Keytruda, indicating insufficient efficacy of its combination therapy, which may impact the company's future market competitiveness.
- Study Scale and Results: The Phase 3 study evaluated over 1,500 subjects aged 12 and older, revealing that the combination therapy did not achieve statistical significance in progression-free survival, reflecting limitations in the treatment approach.
- Safety Assessment: Despite the disappointing results, Regeneron stated that the combination therapy did not indicate new safety signals, which may alleviate some investor concerns regarding the drug's safety profile.
- Ongoing Research Plans: Regeneron is currently conducting another Phase 3 trial comparing its combination therapy to Bristol Myers’ (BMY) Opdualag, demonstrating the company's continued exploration of treatment options despite facing challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 712.870
Low
637.00
Averages
808.50
High
1057
Current: 712.870
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Reviews Phase 3 Trial Results for Fianlimab
- Trial Overview: Regeneron's Phase 3 trial did not achieve statistical significance for progression-free survival (PFS), although the high-dose fianlimab combination showed a numeric improvement of 5.1 months in median PFS, indicating that further validation of this treatment regimen is necessary.
- Patient Recruitment: The trial enrolled a total of 1,546 patients, randomized into different treatment groups, with the high-dose combination group (n=508) compared to the pembrolizumab monotherapy group (n=462), revealing a hazard ratio of 0.845, which is close to significance.
- Safety Assessment: No new safety signals were identified during the trial, suggesting that the combination of fianlimab and cemiplimab is comparable in safety to existing treatment options, providing a foundation for future clinical applications.
- Future Plans: Regeneron is conducting another Phase 3 head-to-head trial evaluating the efficacy of the high-dose fianlimab combination against Opdualag®, which is expected to provide additional data support for the clinical use of this drug.
See More
Japanese Teen Wins $100,000 Innovator Award
- Award Winner: 17-year-old Hikaru Kuribayashi from Sapporo, Japan, won the $100,000 George D. Yancopoulos Innovator Award at the 2026 Regeneron International Science and Engineering Fair for his development of a simulation program that aids in understanding complex folding phenomena, showcasing his exceptional talent in scientific research.
- Project Impact: This year's competition attracted over 1,700 young STEM students from 67 countries, with total awards exceeding $7 million, aimed at inspiring the next generation of scientific leaders and promoting scientific innovation and education.
- Technological Application: Kuribayashi's simulation software utilizes a Markov Chain Monte Carlo method, allowing it to analyze multiple folding possibilities simultaneously, which is expected to have a profound impact on the design of devices that require folding, such as satellite solar sails and medical devices.
- Other Awarded Projects: Additionally, Lakshmi Agrawal from Washington and Nikola Veselinov from Bulgaria each received $75,000 Young Scientist Awards for developing a sponge that removes pollutants from water and proposing a new mathematical theorem, respectively, highlighting the innovative potential of young scientists.
See More
Regeneron’s Combination Therapy Fails Late-Stage Trial Against Keytruda
- Trial Failure: Regeneron (REGN) announced that its late-stage trial failed to meet the primary endpoint of progression-free survival against Merck’s (MRK) Keytruda, indicating insufficient efficacy of its combination therapy, which may impact the company's future market competitiveness.
- Study Scale and Results: The Phase 3 study evaluated over 1,500 subjects aged 12 and older, revealing that the combination therapy did not achieve statistical significance in progression-free survival, reflecting limitations in the treatment approach.
- Safety Assessment: Despite the disappointing results, Regeneron stated that the combination therapy did not indicate new safety signals, which may alleviate some investor concerns regarding the drug's safety profile.
- Ongoing Research Plans: Regeneron is currently conducting another Phase 3 trial comparing its combination therapy to Bristol Myers’ (BMY) Opdualag, demonstrating the company's continued exploration of treatment options despite facing challenges.
See More
Regeneron's Fianlimab Trial Fails to Meet Key Goals
- Trial Results: Regeneron's pivotal late-stage melanoma trial for its experimental drug fianlimab, combined with Libtayo, failed to meet its primary endpoint, as the fianlimab arm showed numerical improvement in progression-free survival but lacked statistical significance, leading to a slight decline in stock price during after-hours trading.
- Survival Data: In the high-dose arm, patients had a median progression-free survival of 11.5 months compared to 6.4 months for those on Keytruda alone, indicating a potential benefit but failing to meet clinical trial statistical requirements, highlighting challenges in market competition.
- Market Reaction: Despite 22 out of 29 analysts rating Regeneron stock as 'Buy' or higher, retail sentiment on Stocktwits remained bearish, reflecting concerns about the company's future performance, especially with the investigational status of the drug.
- Future Outlook: Regeneron is continuing a separate late-stage trial comparing the same combination against Bristol Myers Squibb’s Opdualag; although this trial's results are disappointing, the company is striving to establish a foothold in the rapidly growing melanoma immunotherapy market, with full results to be presented at an upcoming medical meeting.
See More
2026 Regeneron International Science and Engineering Fair Winners Announced
- Innovator Award Winner: 17-year-old Hikaru Kuribayashi from Sapporo, Japan, won the $100,000 George D. Yancopoulos Innovator Award for his simulation program that understands complex folding, showcasing the potential and creativity of young scientists.
- Environmental Impact: 18-year-old Lakshmi Agrawal from Bellevue, Washington, received the $75,000 Young Scientist Award for her sponge filter that removes 80% of pollutants from water, demonstrating significant contributions to protecting aquatic ecosystems.
- Mathematical Breakthrough: 17-year-old Nikola Veselinov from Sofia, Bulgaria, won the $75,000 Young Scientist Award for describing conditions under which certain equations cannot be solved using basic math functions, potentially impacting equations in physics and motion.
- Global Participation: The 2026 fair attracted over 1,700 young STEM students from 67 countries and regions, awarding more than $7 million, emphasizing the importance of science education for future leaders.
See More
Regeneron ISEF Awards Highlight Young Innovators' Achievements
- Award Recognition: 17-year-old Hikaru Kuribayashi from Japan won the $100,000 George D. Yancopoulos Innovator Award for his simulation program that predicts complex folding, showcasing the potential of young scientists to drive future scientific research.
- Environmental Technology Breakthrough: 18-year-old Lakshmi Agrawal from Washington received a $75,000 award for her sponge that removes pollutants from water, demonstrating significant implications for protecting aquatic ecosystems and potentially leading the way for future environmental technologies.
- Mathematical Theory Innovation: 17-year-old Nikola Veselinov from Bulgaria was awarded $75,000 for his new theorem that describes conditions under which certain equations cannot be solved using basic math functions, which may have profound implications for physics and the study of motion in space.
- Global Participation: The 2026 Regeneron International Science and Engineering Fair attracted over 1,700 young STEM students from 67 countries, highlighting the immense potential and diversity of youth in scientific research and fostering international scientific collaboration.
See More
Regeneron Reviews Phase 3 Trial Results for Fianlimab
- Trial Overview: Regeneron's Phase 3 trial did not achieve statistical significance for progression-free survival (PFS), although the high-dose fianlimab combination showed a numeric improvement of 5.1 months in median PFS, indicating that further validation of this treatment regimen is necessary.
- Patient Recruitment: The trial enrolled a total of 1,546 patients, randomized into different treatment groups, with the high-dose combination group (n=508) compared to the pembrolizumab monotherapy group (n=462), revealing a hazard ratio of 0.845, which is close to significance.
- Safety Assessment: No new safety signals were identified during the trial, suggesting that the combination of fianlimab and cemiplimab is comparable in safety to existing treatment options, providing a foundation for future clinical applications.
- Future Plans: Regeneron is conducting another Phase 3 head-to-head trial evaluating the efficacy of the high-dose fianlimab combination against Opdualag®, which is expected to provide additional data support for the clinical use of this drug.
See More
Japanese Teen Wins $100,000 Innovator Award
- Award Winner: 17-year-old Hikaru Kuribayashi from Sapporo, Japan, won the $100,000 George D. Yancopoulos Innovator Award at the 2026 Regeneron International Science and Engineering Fair for his development of a simulation program that aids in understanding complex folding phenomena, showcasing his exceptional talent in scientific research.
- Project Impact: This year's competition attracted over 1,700 young STEM students from 67 countries, with total awards exceeding $7 million, aimed at inspiring the next generation of scientific leaders and promoting scientific innovation and education.
- Technological Application: Kuribayashi's simulation software utilizes a Markov Chain Monte Carlo method, allowing it to analyze multiple folding possibilities simultaneously, which is expected to have a profound impact on the design of devices that require folding, such as satellite solar sails and medical devices.
- Other Awarded Projects: Additionally, Lakshmi Agrawal from Washington and Nikola Veselinov from Bulgaria each received $75,000 Young Scientist Awards for developing a sponge that removes pollutants from water and proposing a new mathematical theorem, respectively, highlighting the innovative potential of young scientists.
See More
Regeneron’s Combination Therapy Fails Late-Stage Trial Against Keytruda
- Trial Failure: Regeneron (REGN) announced that its late-stage trial failed to meet the primary endpoint of progression-free survival against Merck’s (MRK) Keytruda, indicating insufficient efficacy of its combination therapy, which may impact the company's future market competitiveness.
- Study Scale and Results: The Phase 3 study evaluated over 1,500 subjects aged 12 and older, revealing that the combination therapy did not achieve statistical significance in progression-free survival, reflecting limitations in the treatment approach.
- Safety Assessment: Despite the disappointing results, Regeneron stated that the combination therapy did not indicate new safety signals, which may alleviate some investor concerns regarding the drug's safety profile.
- Ongoing Research Plans: Regeneron is currently conducting another Phase 3 trial comparing its combination therapy to Bristol Myers’ (BMY) Opdualag, demonstrating the company's continued exploration of treatment options despite facing challenges.
See More
Regeneron's Fianlimab Trial Fails to Meet Key Goals
- Trial Results: Regeneron's pivotal late-stage melanoma trial for its experimental drug fianlimab, combined with Libtayo, failed to meet its primary endpoint, as the fianlimab arm showed numerical improvement in progression-free survival but lacked statistical significance, leading to a slight decline in stock price during after-hours trading.
- Survival Data: In the high-dose arm, patients had a median progression-free survival of 11.5 months compared to 6.4 months for those on Keytruda alone, indicating a potential benefit but failing to meet clinical trial statistical requirements, highlighting challenges in market competition.
- Market Reaction: Despite 22 out of 29 analysts rating Regeneron stock as 'Buy' or higher, retail sentiment on Stocktwits remained bearish, reflecting concerns about the company's future performance, especially with the investigational status of the drug.
- Future Outlook: Regeneron is continuing a separate late-stage trial comparing the same combination against Bristol Myers Squibb’s Opdualag; although this trial's results are disappointing, the company is striving to establish a foothold in the rapidly growing melanoma immunotherapy market, with full results to be presented at an upcoming medical meeting.
See More
2026 Regeneron International Science and Engineering Fair Winners Announced
- Innovator Award Winner: 17-year-old Hikaru Kuribayashi from Sapporo, Japan, won the $100,000 George D. Yancopoulos Innovator Award for his simulation program that understands complex folding, showcasing the potential and creativity of young scientists.
- Environmental Impact: 18-year-old Lakshmi Agrawal from Bellevue, Washington, received the $75,000 Young Scientist Award for her sponge filter that removes 80% of pollutants from water, demonstrating significant contributions to protecting aquatic ecosystems.
- Mathematical Breakthrough: 17-year-old Nikola Veselinov from Sofia, Bulgaria, won the $75,000 Young Scientist Award for describing conditions under which certain equations cannot be solved using basic math functions, potentially impacting equations in physics and motion.
- Global Participation: The 2026 fair attracted over 1,700 young STEM students from 67 countries and regions, awarding more than $7 million, emphasizing the importance of science education for future leaders.
See More
Regeneron ISEF Awards Highlight Young Innovators' Achievements
- Award Recognition: 17-year-old Hikaru Kuribayashi from Japan won the $100,000 George D. Yancopoulos Innovator Award for his simulation program that predicts complex folding, showcasing the potential of young scientists to drive future scientific research.
- Environmental Technology Breakthrough: 18-year-old Lakshmi Agrawal from Washington received a $75,000 award for her sponge that removes pollutants from water, demonstrating significant implications for protecting aquatic ecosystems and potentially leading the way for future environmental technologies.
- Mathematical Theory Innovation: 17-year-old Nikola Veselinov from Bulgaria was awarded $75,000 for his new theorem that describes conditions under which certain equations cannot be solved using basic math functions, which may have profound implications for physics and the study of motion in space.
- Global Participation: The 2026 Regeneron International Science and Engineering Fair attracted over 1,700 young STEM students from 67 countries, highlighting the immense potential and diversity of youth in scientific research and fostering international scientific collaboration.
See More
